Abstract
BackgroundNatural killer (NK) cells have been known to contribute to surveillance and control of hepatocellular carcinoma (HCC). However, the association of NK cell activity with stage and recurrence risk of HCC have not been fully evaluated.MethodsUntreated patients with newly diagnosed HCC were prospectively enrolled. Peripheral blood mononuclear cells were isolated at the time of diagnosis. Patients who had undergone surgery or radiofrequency ablation were classified as the curative treatment group, and their blood samples were collected again at 1 month after treatment.ResultsA total of 80 patients with HCC were enrolled. The mean age was 62.5 years. At baseline, interferon (IFN)-γ producing NK cell proportion was significantly lower in patients with Barcelona clinic liver cancer (BCLC) stage B, C, or D than in those with BCLC stage 0 (42.9% vs. 56.8%, P = 0.045). Among all patients, 56 patients had undergone curative treatment, and 42 patients re-visited at 1 month after curative treatment. There was no significant change in total NK cell and IFN-γ producing NK cell proportion from baseline to 1 month after treatment (all P > 0.05). During a median follow-up of 12.4 months, HCC recurred in 14 patients (33.3%). When patients were classified according to the IFN-γ producing NK cell proportion (group 1, ≥ 45%; and group 2, < 45%), HCC recurrence rate did not differ according to the IFN-γ producing NK cell proportion at baseline (log-rank test, P = 0.835). However, patients with < 45% IFN-γ producing NK cell proportion at 1 month after treatment had a significantly higher HCC recurrence rate than patients with that of ≥ 45% (log-rank test, P < 0.001). Multivariate analysis revealed that BCLC stage B (hazard ratio [HR] = 3.412, P = 0.045) and < 45% IFN-γ producing NK cell proportion at 1 month after treatment (HR = 6.934, P = 0.001) independently predicted an increased risk of HCC recurrence.ConclusionsDecreased NK cell activity is significantly associated with the advanced stage of HCC, and the increased recurrence risk of HCC after curative treatment.
Highlights
Natural killer (NK) cells have been known to contribute to surveillance and control of hepatocellular carcinoma (HCC)
Patients were divided into two groups according to the treatment modality: (1) patients treated with surgical resection or radiofrequency ablation (RFA) and (2) patients treated with therapies other than resection or RFA, including best supportive care (Additional file 1: Fig. 1)
IFN‐γ producing NK cell proportion at 1 month after curative treatment significantly predicted HCC recurrence Among 42 patients who re-visited at 1 month after curative treatment, HCC recurred in 14 patients (33.3%) during the median follow-up of 12.4 months
Summary
Natural killer (NK) cells have been known to contribute to surveillance and control of hepatocellular carcinoma (HCC). The association of NK cell activity with stage and recurrence risk of HCC have not been fully evaluated. Hepatocellular carcinoma (HCC) is currently the second leading cause of cancer-related mortalities worldwide [1], and have poor prognosis with high recurrence rate even in patients with early stage HCC treated with curative modality [2,3,4,5]. It has been indicated that immune cells in the tumor microenvironment play a critical role in defense against HCC progression [12, 13]. The first host defense against tumor is innate immunity, and the liver contains a substantial number of various innate lymphocytes including natural killer (NK) cells [14, 15]. NK cells account for a large proportion of innate lymphocytes, and are significantly involved in innate and adaptive immunological defense against cancer development [16]
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have